Actively Recruiting
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
Led by China National Center for Cardiovascular Diseases · Updated on 2025-12-04
700
Participants Needed
1
Research Sites
279 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.
CONDITIONS
Official Title
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 3 months to 85 years, no sex preference
- Right heart catheter showing mean pulmonary artery pressure (mPAP) ≥ 25 mmHg
- Pulmonary vascular resistance (PVR) > 3 Wood units (in children PVRi > 3 WU x m2)
- Pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg at rest
- Diagnosed with group 1, 2, 4, or 5 pulmonary hypertension according to WHO classification
- Taking at least one pulmonary hypertension targeted drug or calcium antagonist
- Signed written informed consent
You will not qualify if you...
- Pulmonary hypertension related to left heart disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100037
Actively Recruiting
Research Team
T
Tingting Guo, M.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here